Table 1 Baseline characteristics of participants.

From: A novel visceral adiposity index predicts bone loss in female early rheumatoid arthritis patients detected by HR-pQCT

 

Healthy control (n = 100)

Female ERA (n = 104)

P value

Age (years)

46 ± 6

48 ± 11

0.291

Height (cm)

161 ± 5

160 ± 8

0.343

Weight (kg)

59.4 ± 14.2

57.4 ± 9.4

0.150

BMI (kg/m2)

20.6 ± 2.4

21.4 ± 2.5

0.109

WC (cm)

70.7 ± 6.7

78.9 ± 6.7

0.002

HDL-C (mmol/L)

1.61 ± 0.52

1.46 ± 0.40

0.497

TG (mmol/L)

0.95 ± 0.56

1.02 ± 0.47

0.317

CVAI

41.12 ± 20.89

55.10 ± 32.02

0.010

VAI

63.75 ± 59.74

65.72 ± 38.67

0.870

Overweight/obesity

26 (26.0%)

28 (26.9%)

1.000

Visceral obesity

20 (20%)

31 (29.8%)

0.145

ESR (mm/h)

17.8 ± 2.3

64.1 ± 32.0

0.000

CRP (mg/L)

1.1 ± 0.6

20.9 ± 26.8

0.000

Disease duration (month)

NA

7.2 ± 6.3

 

HAQ (0–3)

NA

1.1 ± 0.7

Tender joint count (0–68)

NA

8 (5–13)

Swollen joint count (0–66)

NA

5 (3–7)

Damage joint count (0–68)

NA

2 (1–4)

DAS 28-CRP

NA

5.0 ± 1.0

DAS 28-ESR

NA

6.9 ± 1.1

SDAI score

NA

29.7 ± 11.6

Biologic DMARDs

NA

0

MTX

NA

9

Leflunomide

NA

1

Sulfasalazine

NA

2

Hydroxychloroquine

NA

6

Glucocorticord

NA

19

NSAIDs use

NA

82

  1. BMI: body mass index; WC: waist circumference; FBG: fasting blood glucose; LDL: low density lipoprotein; HDL: high density lipoprotein; TC: total cholesterol; TG: triglyceride; CVAI: Chinses visceral adiposity index; VAI: visceral adiposity index; ESR: erythrocyte sedimentation rate; CRP: C- response protein; HAQ: Health Assessment Questionnaire; DAS28: Disease Activity Score in 28 joints; SDAI: Simple Disease Activity Index Score; DMARD, disease modifying anti-rheumatic drugs; MTX, Methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs. P value: healthy control & ERA.
Back to article page